Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Maria K Svensson"'
Publikováno v:
Upsala Journal of Medical Sciences, Vol 127, Pp 1-7 (2022)
Background: The hemodialysis (HD) population has been a vulnerable group during the coronavirus disease 2019 (COVID-19) pandemic. Advanced chronic kidney disease with uremia is associated with weaker immune response to infections and an attenuated re
Externí odkaz:
https://doaj.org/article/0aba747159a34883966ea38db49cf83f
Autor:
Johan Sundström, Johan Ärnlöv, Stelios Karayiannides, Johan Bodegard, Karolina Ersmark, Stefan Gustafsson, Thomas Cars, Maria K. Svensson, Anna Norhammar
Publikováno v:
ESC Heart Failure, Vol 11, Iss 3, Pp 1377-1388 (2024)
Abstract Aims This study aimed to characterize a contemporary population with subtypes of incident or prevalent heart failure (HF) based on reduced (HFrEF), mildly reduced, or preserved (HFpEF) left ventricular ejection fraction (LVEF) and to assess
Externí odkaz:
https://doaj.org/article/899c8b0a6e57407cb92948c2e9448a93
Autor:
Maria K. Svensson, Stefan James, Annica Ravn-Fischer, Guillermo Villa, Lovisa Schalin, Thomas Cars, Stefan Gustafsson, Emil Hagström
Publikováno v:
Upsala Journal of Medical Sciences, Vol 129, Pp 1-10 (2024)
Background: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduces low-density lipoprotein cholesterol (LDL-C) levels and decreases the incidence of major ischaemic events in clinical trials. However, less is known ab
Externí odkaz:
https://doaj.org/article/6a82235f13f94afb98a696585deb3a07
Autor:
Hanna Jansson, Aso Saeed, Maria K. Svensson, Kristina Finnved, Mikael Hellström, Gregor Guron
Publikováno v:
Kidney & Blood Pressure Research, Pp 1-11 (2019)
Background/Aim: Calcifications of large arteries are frequent in chronic kidney disease (CKD) and may contribute to the high cardiovascular risk in this population. The aim of this study was to examine whether abdominal aortic calcification volume (A
Externí odkaz:
https://doaj.org/article/a369d669ef0b429fb8ac8467d59e7b90
Autor:
My Samuelsson, Jonatan Dereke, Maria K. Svensson, Mona Landin-Olsson, Magnus Hillman, on the behalf of the DISS Study group
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 9, Iss 1, Pp 1-6 (2017)
Abstract Background The aim of this study was to investigate plasma levels of sST2 and sCD163 to determine whether they at an early stage could predict development of diabetic nephropathy and/or diabetic retinopathy in patients at clinical onset. Met
Externí odkaz:
https://doaj.org/article/9f81ba9ce67340a9833642350e135fa0
Autor:
Fozia Ahmed, Prasad G Kamble, Susanne Hetty, Giovanni Fanni, Milica Vranic, Assel Sarsenbayeva, Robin Kristófi, Kristina Almby, Maria K Svensson, Maria J Pereira, Jan W Eriksson
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 107:e1879-e1889
Context Reduced estrogen levels in postmenopausal women predispose them to metabolic side effects, including insulin resistance and type 2 diabetes; however, the cellular mechanisms are not well understood. Objective This work aimed to study the expr
Autor:
Bo Freyschuss, Maria K. Svensson, Thomas Cars, Lars Lindhagen, Helena Johansson, Andreas Kindmark
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 37(4)
Results from real-world evidence (RWE) from the largest healthcare region in Sweden show low uptake of antiresorptive (AR) treatment, but beneficial effect in those receiving treatment, especially for the composite outcome of hip fracture or death. F
Autor:
Maria K. Svensson, Francesc Sorio Vilela, Margrét Leósdóttir, Jonas Banefelt, Maria Lindh, Alexander Rieem Dun, Anna Norhammar, Guillermo Villa
Publikováno v:
Upsala journal of medical sciences. 127
Background: Oral lipid-lowering treatment (LLT) is the standard of care for patients with cardiovascular disease (CVD). However, insufficient treatment intensity and poor adherence can lead to suboptimal treatment benefit, rendering patients at incre
Autor:
MARIA J. Pereira, MILICA VRANIC, PRASAD G. KAMBLE, HENNING JERNOW, ROBIN KRISTÓFI, EMA HOLBIKOVA, STANKO SKRTIC, JOEL KULLBERG, MARIA K. SVENSSON, SUSANNE HETTY, JAN W. ERIKSSON
Publikováno v:
Translational research : the journal of laboratory and clinical medicine. 242
CDKN2C/p18 (Cyclin-Dependent Kinase Inhibitor 2C) is a cell growth regulator that controls cell cycle progression and has previously been associated with increased risk for type II diabetes (T2D) and reduced peripheral adipose tissue (AT) storage cap